Advancing the First Implantable Immune Organs to Treat Ovarian Cancer: Wyss Institute’s iNodes team receives ARPA-H Sprint for Women’s Health Award

Ovarian cancer is more deadly than any other type of female reproductive organ cancer. It is estimated that in 2024, in the U.S. alone, more than 12,000 women will die from the disease because available therapies are not effective. To help overcome this striking deficit in women’s health, ARPA-H has selected a team at the Wyss Institute at Harvard University as an awardee of its Sprint for Women’s Health effort to develop “iNodes” – implantable lymphoid organs containing patients’ immune cells – as an entirely novel form of personalized immunotherapy to treat ovarian cancer.